Journal of Clinical Endocrinology & Metabolism, Vol 58, 110-120, Copyright © 1984 by Endocrine Society

ARTICLES

Serum levels of type I and III procollagen fragments in Paget's disease of bone

LS Simon, SM Krane, PD Wortman, IM Krane and KL Kovitz

Patients with Paget's disease of bone were found to have elevated serum levels of type I procollagen carboxyterminal peptide (pColl-I-C) which correlated with other measurements of disease activity. The elevated levels of pColl-I-C decreased within hours after the injection of salmon calcitonin and within weeks after oral dichloromethylene diphosphonate treatment. The decrease in serum pColl-I-C after a single injection of salmon calcitonin was associated with a decrease in urinary hydroxyproline excretion, both of which rose toward pretreatment values within 7 h. The pColl-I-C levels remained normal for months after dichloromethylene diphosphonate therapy was discontinued. Using a RIA for the type III procollagen amino-terminal peptide (pColl-III-N), it was found that serum levels were also elevated in patients with Paget's disease. The levels of pColl-III-N also decreased after the injection of salmon calcitonin, but not to the same extent as those of pColl-I-C. After chronic therapy with dichloromethylene diphosphonate, serum levels of pColl-III-N decreased, but not into the normal range. We postulate that whereas pColl-I-C is derived from synthesis of mineralized bone collagen, pColl-III-N is derived from the loose fibrous stroma replacing marrow in areas closely associated with active Pagetic bone disease.

This article has been cited by other articles:

				T. Horiguchi, S. Tachikawa, R. Kondo, M. Hirose, S. Teruya, A. Ishibashi, and K. Banno Usefulness of Serum Carboxy-Terminal Telopeptide of Type I Collagen (ICTP) as a Marker of Bone Metastasis from Lung Cancer Jpn. J. Clin. Oncol., April 1, 2000; 30(4): 174 - 179. [Abstract] [Full Text] [PDF]